a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .
Efficacy and Safety of Iparomlimab and Tuvonralimab(QL1706) Combined With Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy for High-risk Locally Advanced Cervical Cancer：a Single Arm, Phase II Multicenter Clinical Study
Sponsor: Cancer Center of the First Affiliated Hospital of Soochow University
A PHASE2 clinical study on Cervical Cancer Metastatic and Cervical Cancer Stage IVA, this trial is actively recruiting participants. The trial is conducted by Cancer Center of the First Affiliated Hospital of Soochow University and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recordedEligibility Summary
No eligibility information available.
Contact Information
- Cancer Center of the First Affiliated Hospital of Soochow University
- Cancer Hospital of The University of Chinese Academy of Sciences
- First Affiliated Hospital of Ningbo University
- First Affiliated Hospital of Zhejiang University
- First Hospital of Zhejiang University
- Henan Provincial People's Hospital
- Jinhua Municipal Central Hospital
- People's Hospital of Quzhou
- Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
- The First Affiliated Hospital of Nanchang University
- Wenzhou Central Hospital
- Xiangya Hospital of Central South University
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.